Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils.
Propionibacterium acnes (P. acnes), an anaerobic pathogen, plays an important role in the pathogenesis of acne and seems to initiate the inflammatory process by producing neutrophil chemotactic factors (NCF). Once neutrophils attracted by bacterial chemoattractants reach the inflamed site, they release inflammatory mediators such as lysosomal enzymes and reactive oxygen species (ROS). Previously, it has been shown that antibiotics may affect acne by means other than their anti-bacterial effects. Thus, we investigated the effect of subminimal inhibitory concentration (sub-MIC) of tetracycline and erythromycin on production of NCF and ROS. NCF was tested in vivo in a mouse model and ROS was estimated on human PMNL in vitro, by nitroblue tetrazolium dye reduction test (NBT) and cytochrome-C reduction test. Tetracycline (CS-T) and Erythromycin (CS-E) treated cultures showed a significant reduction of 35.8% and 58.3% in NCF production respectively, as compared to P. acnes stimulated cultures. Tetracycline and erythromycin at their sub-MIC also significantly inhibited release of ROS from human PMNL. Thus, tetracycline and erythromycin, besides having antibacterial activity, also have an anti-inflammatory action. These antibiotics reduce the capacity of P. acnes to produce NCF, as well decrease its ability to induce ROS from PMNL.
Jain
A
A
Department of Microbiology, King George's Medical College, Lucknow-226003, INDIA.
Sangal
L
L
Basal
E
E
Kaushal
G P
GP
Agarwal
S K
SK
D000152:Acne Vulgaris / Q000188:drug therapy; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002630:Chemotactic Factors / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D003574:Cytochrome c Group / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination / Q000494:pharmacology* / Q000627:therapeutic use; D004917:Erythromycin / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects* / Q000201:enzymology / Q000276:immunology* / Q000382:microbiology; D010084:Oxidation-Reduction / Q000187:drug effects; D011425:Propionibacterium acnes / Q000187:drug effects / Q000276:immunology* / Q000472:pathogenicity; D017382:Reactive Oxygen Species / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013481:Superoxides / Q000037:antagonists & inhibitors / Q000378:metabolism; D013752:Tetracycline / Q000494:pharmacology* / Q000627:therapeutic use; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D002630:Chemotactic Factors; D003574:Cytochrome c Group; D017382:Reactive Oxygen Species; D013481:Superoxides; D004917:Erythromycin; D013752:Tetracycline